In a nutshell This study aimed to investigate the safety and effectiveness of two venetoclax (Venclexta) treatment regimes in non-Hodgkin lymphoma patients. This study concluded that one of these regimes was safe and showed effectiveness in these patients. The recommended dose of venetoclax was also found. Some background New therapies...
Read MoreNon-Hodgkin lymphoma Posts on Medivizor
Searching for participants to try a new combination of targeted therapy for relapsed or non-responsive B-cell lymphomas.
In a nutshell This study is investigating the effectiveness of a new combination of treatments, nivolumab (Opdivo) and varlilumab (CDX-1127), for non-responsive, aggressive B-cell lymphomas. The main outcome that will be measured is the proportion of patients that respond to treatment (overall response rate). This trial is recruiting in the US. The...
Read MoreSearching for patients with lymphoma or leukemia to test T-cell therapy after stem cell transplantation
In a nutshell This phase 2 trial is evaluating how well CD8+ memory T-cell therapy works in patients with leukemia or lymphoma after a stem cell transplant (SCT). The main outcome to be measured will be the number of patients who have full chimerism (donor cells work completely and only donor cells can be identified after transplant) after therapy. This...
Read MoreEvaluating polatuzumab vedotin and pinatuzumab vedotin for relapsed or refractory NHL
In a nutshell This study evaluated the safety and effectiveness of rituximab (Rituxan) combined with either polatuzumab vedotin (pola) or pinatuzumab vedotin (pina) for patients with non-Hodgkin’s lymphoma (NHL) that has come back or stopped responding to treatment. This study concluded that pola was associated with better...
Read MoreCombination of ublituximab, umbralisib and ibrutinib for patients with leukemia and lymphoma
In a nutshell This study aimed to investigate the safety and effectiveness of ublituximab, umbralisib and ibrutinib combination in patients with non-Hodgkin lymphoma (NHL). This study concluded that this combination appears safe and effective for these patients. Some background Patients with NHL are often treated with targeted therapies....
Read MoreCRISPR
Since the Human Genome Project published the first draft of the human genome in February 2001, there has been a boom in research and new technologies around genetics. The project revealed that humans have around 20,500 genes. Around 3 million base pairs make up these genes. CRISPR is a new technology that has arisen from this groundbreaking Human Genome...
Read MoreEvaluating rituximab maintenance therapy versus observation for follicular lymphoma
In a nutshell This study evaluated the effectiveness of rituximab (Rituxan) maintenance therapy for patients with follicular lymphoma (FL) after frontline treatment with BR (bendamustine, rituximab). This study concluded that rituximab maintenance is effective for these patients. Some background Chemoimmunotherapy containing rituximab remains the...
Read MoreEvaluating rituximab plus lenalidomide for recurrent or non-responsive indolent non-Hodgkin lymphoma
In a nutshell This study evaluated the safety and effectiveness of rituximab (Rituxan) plus lenalidomide (Revlimid) for patients with recurrent or non-responsive non-Hodgkin’s lymphoma (NHL). This study concluded that lenalidomide was well-tolerated and improved the effectiveness of rituximab in these patients. Some background Follicular...
Read MoreThe role of red cell distribution width in mantle cell lymphoma
In a nutshell This study aimed to investigate the prognostic role of red cell distribution width (RDW) in mantle cell lymphoma. This study concluded that RDW could be a prognostic factor in these patients. Some background The red cell distribution width (RDW) is a measurement of the amount that red blood cells vary in size. It is...
Read MoreOfatumumab to treat previously untreated follicular lymphoma
In a nutshell This study aimed to investigate the safety and effectiveness of ofatumumab in patients with untreated, advanced stage follicular lymphoma. This study concluded that ofatumumab is safe and effective in these patients. Some background Rituximab (Rituxan) is a targeted therapy that has proven effective in treating...
Read MoreEvaluating chemotherapy regimens before stem cell transplantation for patients with non-Hodgkin’s lymphoma
In a nutshell This study evaluated the effectiveness of BEAM chemotherapy versus BUCYVP16 chemotherapy in patients with non-Hodgkin’s lymphoma (NHL) before autologous stem cell transplantation (ASCT). This study concluded that these regimens were similarly safe and effective for these patients before ASCT. Some background For patients with NHL...
Read MoreSearching for patients with relapsed or unresponsive follicular lymphoma to trial a new drug
In a nutshell This trial will evaluate the effects of a new treatment parsaclisib (INCB050465) in relapsed or unresponsive follicular lymphoma (FL). Response rate, survival, and side effects will be the main outcomes measured. The details Many patients are cured with treatments for follicular lymphoma (FL). Some, however, lose response to therapy...
Read More
